# Ipamorelin Dosage Research: The Studied Doses, Routes, and Half-Life > Ipamorelin dosage in research context only: the human IV doses, rat subcutaneous regimens, the ~2-hour half-life, and why the CJC-1295 stack 'protocols' have no controlled human dosing basis. No recommendations. Human IV ranges, rodent subcutaneous regimens, the ~2-hour half-life, and the honest fact that the popular stack protocols rest on no controlled human data. ## Read this first This page reports ipamorelin dosage the way the published studies reported it — which doses were given, to which species, by which route, for how long. It is not a protocol and contains no recommendation. There is a specific reason for that beyond house rules: no controlled human study has ever established a safe or effective ipamorelin dose for any wellness use. The human doses on record were given by IV in a hospital research setting [2][3]; the rest are animal doses [4][5]. The popular "how much CJC-1295 ipamorelin should I take" question has no evidence-based answer, because the combination has never been dose-finding-tested in a controlled human trial [13][17]. Everything below is framed as what was administered in a study, in the third person, with no instruction for any reader. The numbers are here for understanding the pharmacology, not for use. ## The doses that appear in the literature **Human (IV, research and trial settings).** The pharmacokinetic study used five 15-minute IV infusions of 4.21, 14.02, 42.13, 84.27, and 140.45 nmol/kg as single doses [2]. The Phase 2 ileus trial used 0.03 mg/kg IV twice daily for up to 7 days [3]. Both were intravenous and clinician-administered; neither supports any self-administration regimen. **Rat (subcutaneous and IV).** The bone-growth study used 18, 90, and 450 micrograms/day subcutaneously, split three times daily for 15 days [4]. A bone-mineral study used 0.5 mg/kg/day by continuous subcutaneous minipump for 12 weeks. A postoperative-ileus model used 0.1–1 mg/kg IV repeated four times daily. **Ferret (2024).** The cisplatin weight-loss study used 1–3 mg/kg intraperitoneally [5]. **Community stack protocols.** Forum and clinic regimens pair ipamorelin with CJC-1295 subcutaneously. These have no peer-reviewed human dosing basis and are described here only as anecdotal practice, not as recommendations. ## Half-life and pharmacokinetics Ipamorelin's terminal half-life in healthy human volunteers is approximately 2 hours (IV), with clearance of 0.078 L/h/kg and a steady-state volume of distribution of 0.22 L/kg [2]. The growth-hormone response is a single discrete pulse peaking around 40 minutes (0.67 h) after dosing [2]. In rats, plasma clearance is roughly 5-fold lower than GHRP-6, and intranasal bioavailability is about 20%. The practical reading: ipamorelin produces a brief, sharp growth-hormone pulse and then clears quickly — the pharmacology of a short-acting secretagogue, which is precisely why community protocols pair it with a long-acting GHRH analog whose action persists across days [13]. ## How much cjc-1295 ipamorelin should i take There is no evidence-based dose to report. No controlled human trial has performed dose-finding for the CJC-1295 + ipamorelin combination, so any specific microgram figure circulating online is community convention, not a studied dose [13][17]. What the literature does support is the single-agent pharmacology: ipamorelin's human exposure was studied only by IV [2][3], and CJC-1295's published doses were 30–60 micrograms/kg subcutaneously in pharmacokinetic studies [13]. Combining them into a self-administered "protocol" extrapolates well beyond anything tested. This site does not provide a dose, a titration schedule, or an administration instruction for the combination. ## How to reconstitute cjc-1295 ipamorelin 5mg Reconstitution is a handling question, and the answer here is general and non-prescriptive. Ipamorelin is supplied as a lyophilized (freeze-dried) powder, as either the free base or the acetate salt, and is reconstituted with bacteriostatic water for research handling. As a peptide it degrades with heat and repeated freeze-thaw, so reconstituted solution is typically kept refrigerated. These are general peptide-handling observations drawn from the research-supply literature — not a clinical preparation instruction, not a dosing volume, and not guidance for human use. The specific milligram-to-milliliter math that determines a dose is exactly the step this site does not provide, because a finished combination product has no validated human dosing standard. --- A trading-desk reading of the ipamorelin and combination-stack record — the selective GH pulse logged first as the one clean number, the CJC-1295 pairing read as class-level pharmacology rather than a tested product, and the failed human trial and missing long-term safety left openly unhedged; no clinic behind the console and nothing here dosed, stacked, prescribed, or sold.